1. Introduction {#sec1-ijms-19-02148}
===============

Dysregulation of nutrient homeostasis is a common character of metabolic disorders, such as obesity, diabetes, cardiovascular diseases and fatty liver disease. Nutrient homeostasis is tightly maintained via the balance between energy production and energy utilization. The rapid increase in the prevalence of obesity-related metabolic diseases, such as diabetes, hyperlipidemia, hypertension and cancer, is a serious health problem worldwide \[[@B1-ijms-19-02148]\]. Obesity occurs when an individual's caloric intake exceeds their energy expenditure. In obese individuals, fat accumulates in white adipose tissues (WATs) and in a variety of other tissues. In turn, obesity results in insulin resistance, which leads to obesity-related metabolic disorders.

Peroxisome proliferative-activated receptors (PPARs) include PPARα, PPARβ/δ and PPARγ. Upon ligand binding, PPARs form the complexes with the retinoid X receptor and bind to PPAR response elements (PPREs) in the promoter of these target genes. PPARα is predominantly expressed in the liver and WATs but not in skeletal muscles \[[@B2-ijms-19-02148]\]. PPARα controls fatty acid transport and β-oxidation and improves plasma lipid profiles by decreasing triglyceride (TG) levels and increasing high-density lipoprotein (HDL) cholesterol levels. Thus, PPARα has a crucial role in the regulation of lipid metabolism. Fibrates including gemfibrozil, bezafibrate and fenofibrate are synthetic PPARα agonists that decrease plasma TG levels and increase HDL-cholesterol levels in patients with hyperlipidemia and Type 2 diabetes, thereby preventing coronary heart disease and stroke \[[@B3-ijms-19-02148],[@B4-ijms-19-02148],[@B5-ijms-19-02148],[@B6-ijms-19-02148],[@B7-ijms-19-02148]\]. In addition, treatment with PPARα agonists in animal models of obesity attenuates adiposity and adipocyte hypertrophy and improves glucose metabolism defects, such as hyperglycemia, glucose intolerance and insulin resistance \[[@B2-ijms-19-02148],[@B8-ijms-19-02148],[@B9-ijms-19-02148]\]. However, these drugs are weak agonists of PPARα and have low substrate selectivity, resulting in the need for high doses clinically. Therefore, a more potent and selective PPARα agonist is needed for patients with metabolic syndrome. Pemafibrate (K-877), a novel selective PPARα modulator SPPARMα, increases PPARα transcriptional activity \[[@B10-ijms-19-02148],[@B11-ijms-19-02148]\] and elicits greater PPARα activation than fibrates, with lower EC~50~ values and higher PPAR subtype selectivity \[[@B12-ijms-19-02148]\]. Pemafibrate has an acidic region as fibrates, which contains unique benzoxazole and phenoxyalkyl side-chains, thereby leading to a greater activation of PPARα transcriptional activity and selectivity \[[@B13-ijms-19-02148]\]. Moreover, while other PPARα agonists bind only with one of the Y-shaped ligand-binding pockets of PPARα, pemafibrate binds to the entire cavity region \[[@B10-ijms-19-02148]\]. However, the effects of pemafibrate on obesity and diabetes remain unknown.

The expression of fibroblast growth factor 21 (FGF21), a hormone secreted by the liver, is regulated by PPARα and cAMP-responsive element-binding protein H (CREBH, encoded by *Creb3l3*) during fasting \[[@B14-ijms-19-02148],[@B15-ijms-19-02148],[@B16-ijms-19-02148],[@B17-ijms-19-02148]\]. FGF21 stimulates hepatic ketogenesis and gluconeogenesis to adapt to fasting \[[@B18-ijms-19-02148]\]. FGF21 activates cellular signaling by binding to a cell-surface receptor complex composed of β-Klotho and an FGF receptor 1 (FGFR1) \[[@B19-ijms-19-02148],[@B20-ijms-19-02148]\]. As both β-Klotho and FGFR1 are abundantly expressed in WATs \[[@B21-ijms-19-02148]\], FGF21 regulates the metabolic processes in WATs, including lipogenesis, lipolysis and fatty acid oxidation \[[@B22-ijms-19-02148],[@B23-ijms-19-02148]\]. FGF21 induces the expression of uncoupling protein 1 (*Ucp1*), a thermogenic gene in WATs, activating energy expenditure \[[@B22-ijms-19-02148],[@B24-ijms-19-02148]\]. FGF21 improves energy homeostasis by increasing hepatic fatty acid oxidation and ketogenesis in the liver, thermogenesis of brown adipose tissue (BAT) and browning of WATs, thereby increasing whole-body energy expenditure in mammals. Therefore, FGF21 is a therapeutic target for obesity and obesity-related metabolic diseases \[[@B25-ijms-19-02148]\].

This study investigates the pharmacological effects of pemafibrate versus those of fenofibrate on the progression of obesity in diet-induced obesity (DIO) mice.

2. Results {#sec2-ijms-19-02148}
==========

2.1. Pemafibrate Suppresses High-Fat Diet (HFD)-Induced Obesity in Mice {#sec2dot1-ijms-19-02148}
-----------------------------------------------------------------------

To compare the effects of PPARα agonists on the progression of obesity, 6-week-old male wild type (WT) mice were fed HFD containing 0.00033% pemafibrate or 0.2% fenofibrate for 12 weeks ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}A). The dose of pemafibrate was optimized to achieve similar effects to that of 0.2% fenofibrate (data not shown). After 12 weeks of pemafibrate or fenofibrate administration, all mice exhibited an apparent reduction in diet-induced adiposity ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}B) and a significantly lower BW ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}C) compared to untreated mice, with no change in food intake in all groups. The liver weights of mice administered either agonist were significantly higher than those of untreated mice ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}D). Previous reports show that both agonists increase liver weight accompanied by hepatocyte hypertrophy \[[@B26-ijms-19-02148],[@B27-ijms-19-02148]\]. The weight of epididymal white adipose tissue (eWAT), inguinal WAT (iWAT) and BAT of mice administered either pemafibrate or fenofibrate was significantly lower than that of untreated mice ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}E--G). The plasma glucose, insulin, TG and free fatty acid (FFA) levels of mice treated with either agonist were significantly lower than those of untreated mice ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}H--J,L). Plasma total cholesterol (TC) levels did not differ between groups ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}K). Consistent with a previous report \[[@B28-ijms-19-02148]\], plasma FGF21 levels were significantly higher in both agonist-administered groups than in untreated mice ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}M). There were no differences in plasma aspartate aminotransferase (AST) levels among mouse groups ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}N). Both agonists significantly increased plasma alanine aminotransferase (ALT) levels but there were no changes between both agonists ([Figure 1](#ijms-19-02148-f001){ref-type="fig"}O). Taken together, these results indicate that the toxicities of both agonists in this study were comparable.

Morphological analysis with hematoxylin and eosin (HE) staining reveals no apparent differences between the mouse groups ([Figure 2](#ijms-19-02148-f002){ref-type="fig"}A). Consistent with this finding, the quantitative analysis of liver lipids including TG and TC revealed no differences between mouse groups ([Figure 2](#ijms-19-02148-f002){ref-type="fig"}B,C). Surprisingly, HE staining analysis of adipose tissues including iWAT, eWAT and BAT shows that treatment with either agonist decreased the adipocyte size and lipid droplet size compared to those of untreated mice ([Figure 2](#ijms-19-02148-f002){ref-type="fig"}D--F). While BAT adipocytes normally have multilocular lipid droplets, HFD administration changed their appearance to that of WAT adipocytes. Pemafibrate completely suppressed these changes ([Figure 2](#ijms-19-02148-f002){ref-type="fig"}F). These effects of pemafibrate were stronger than those of fenofibrate. These results indicate that both PPARα agonists decrease the cell size in WATs and BAT.

2.2. Pemafibrate and Fenofibrate Normalize HFD-Induced Glucose Intolerance and Insulin Resistance {#sec2dot2-ijms-19-02148}
-------------------------------------------------------------------------------------------------

Oral glucose tolerance test (OGTT) results indicate that both PPARα agonists improved the glucose response in DIO mice ([Figure 3](#ijms-19-02148-f003){ref-type="fig"}A,B). During OGTT, plasma glucose and insulin levels of mice administered either agonist were significantly lower than those of untreated mice ([Figure 3](#ijms-19-02148-f003){ref-type="fig"}A,B). The lowering effects of the agonists were similar but the glucose in pemafibrate-administered mice were lower than those of fenofibrate-administered mice at 15 min after glucose injection ([Figure 3](#ijms-19-02148-f003){ref-type="fig"}A). Results of the insulin tolerance test (ITT) indicate that the plasma glucose level of mice administered with either agonist was markedly lower than that of untreated mice ([Figure 3](#ijms-19-02148-f003){ref-type="fig"}C). These results indicate that both agonists improve insulin resistance and glucose intolerance in DIO mice.

2.3. Pemafibrate and Fenofibrate Activate PPARα-Mediated Gene Expression in the Liver and iWAT but Not eWAT or BAT of DIO Mice {#sec2dot3-ijms-19-02148}
------------------------------------------------------------------------------------------------------------------------------

In mice fed with HFD for 12 weeks, neither agonist changed the expression of *Ppara* and peroxisome proliferative-activated receptor, gamma, coactivator 1 alpha (*Ppargc1a*) in the liver. However, these mice exhibited a significant increase in other PPARα target genes, including *CrebH*, *Fgf21*, acyl-CoA oxidase 1 (*Acox1*) and carnitine palmitoyl transferase 1a (*Cpt1a*) ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}A). Mice treated with fenofibrate exhibited a greater increase in *CrebH* and *Fgf21* expression than did those treated with pemafibrate ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}A). The two agonists equally increased *Acox1* and *Cpt1a* expression ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}A), which are responsible for fatty acid oxidation. These results indicate that pemafibrate acts as a PPARα agonist and activates fatty acid oxidation in the liver of HFD-fed mice.

In eWAT, pemafibrate did not change *Ppara* expression. Pemafibrate decreased the expression of *Fgf21*, *Ucp1*, cell death-inducing DFFA-like effector a (*Cidea*) and carnitine palmitoyl transferase 1b (*Cpt1b*) ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}B). In contrast, pemafibrate increased the expression of adipose triglyceride lipase (*Atgl*) and hormone sensitive lipase (*Hsl*), the rate-limiting enzymes catalyzing triacylglycerol hydrolysis ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}B). Fenofibrate significantly increased *Ppara* and decreased *Fgf21* expression, with no other changes in expression observed when compared to untreated mice ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}B). Pemafibrate decreased *Ucp1* expression ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}B). These findings indicate that pemafibrate does not increase thermogenesis in eWAT. However, pemafibrate significantly increased *Atgl* and *Hsl* expression ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}B), leading to the induction of lipolysis and subsequent reduction in eWAT weight.

In iWAT, both agonists significantly increased the expression of *Ppara* but not *Pparg* ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C). However, only fenofibrate increased *Ppard* expression ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C), indicating that fenofibrate has an affinity for PPARδ. Both agonists significantly decreased *Fgf21* expression compared to that of untreated mice ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C). A previous report indicates that fenofibrate does not change *Fgf21* expression in the iWAT of DIO mice \[[@B2-ijms-19-02148]\]. Moreover, HFD-induced adiposity increased *Fgf21* expression (data not shown); therefore, the suppression of HFD-induced adiposity by either agonist reduced *Fgf21* expression. Importantly, pemafibrate administration resulted in greater increases in *Ucp1* expression than did fenofibrate ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C). However, either agonist could not change *Ucp2* expression ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C). Both agonists significantly increased the expression of the browning and mitochondria biogenesis markers *Cidea* and *Cpt1b* ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C). Taken together, these data indicate that the suppression of BW gain in HFD feeding by pemafibrate contributes to increased thermogenesis. However, PR domain containing 16 (*Prdm16*), a master regulator of the brown/beige program, did not differ between untreated and pemafibrate-treated mice ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C). In the iWAT of all mice, expressions of adrenergic receptor, beta 3 (*Adrb3*) and the lipolysis genes *Atgl* and *Hsl* were unaltered ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}C).

In BAT, only the expression of *Ppard*, *Fgf21* and ELOVL fatty acid elongase 3 (*Elovl3*), a marker of BAT, were changed in all groups of mice. However, compared to fenofibrate, pemafibrate significantly reduced *Ppard* and *Fgf21* expression in BAT ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}D). Interestingly, the expression of *Elovl3* was significantly elevated in the BAT of mice treated with either agonist when compared to untreated mice ([Figure 4](#ijms-19-02148-f004){ref-type="fig"}D). As Elovl3 is necessary for the synthesis of very long-chain fatty acids as an energy source and full metabolic capacity in BAT \[[@B29-ijms-19-02148]\], both agonists may activate thermogenesis in BAT.

2.4. Pemafibrate Ameliorates Obesity-Induced Abnormalities in Obese Mice {#sec2dot4-ijms-19-02148}
------------------------------------------------------------------------

To investigate whether these drugs can improve obesity-related abnormalities in obese mice, mice were fed HFD for 8 weeks and then fed an HFD plus 0.00033% pemafibrate or 0.2% fenofibrate for 4 weeks ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}A). As seen in [Figure 1](#ijms-19-02148-f001){ref-type="fig"}B, both agonists decreased diet-induced adiposity compared with untreated mice ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}B). BW decreases were significant after 3 weeks of pemafibrate and 1 week of fenofibrate administration when compared to untreated mice ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}C). Pemafibrate-treated mice exhibited a trend toward increased liver weight and decreased eWAT and iWAT weights ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}D--F). Compared with untreated mice, fenofibrate showed no difference in liver, eWAT and iWAT weights ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}D--F). Both agonist administration decreased the BAT weight ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}G). Both agonists significantly and similarly reduced plasma glucose, insulin, TG and FFA levels ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}H--J,L). However, only pemafibrate increased plasma TC levels but not significantly ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}K). Both agonists significantly and similarly increased plasma FGF21 levels ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}M). There was difference in plasma AST levels among mouse groups ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}N). Pemafibrate significantly increased plasma ALT levels compared with untreated mice and there were no differences between two agonists ([Figure 5](#ijms-19-02148-f005){ref-type="fig"}O). Taken together, these results indicate that the toxicities of both agonists used in this study were comparable.

OGTT results show that the plasma glucose levels of mice treated with either agonist were significantly lower than those of untreated mice at 0 and 120 min of testing ([Figure 6](#ijms-19-02148-f006){ref-type="fig"}A). The plasma insulin levels of mice treated with either agonist were significantly lower than those of untreated mice ([Figure 6](#ijms-19-02148-f006){ref-type="fig"}B). ITT results showed no difference in plasma glucose levels between any of the groups of mice; however, at 60 min, mice treated with either agonist exhibited reduced plasma glucose levels compared with untreated mice ([Figure 6](#ijms-19-02148-f006){ref-type="fig"}C).

2.5. Pemafibrate Treatment Alters the Expression of Genes Related to Thermogenesis in iWAT and BAT of Mice Fed with Modest Fat (MF) Diet {#sec2dot5-ijms-19-02148}
----------------------------------------------------------------------------------------------------------------------------------------

Mice fed with MF diet plus 0.001% pemafibrate or 0.2% fenofibrate for 1 week ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}A), as previously optimized \[[@B28-ijms-19-02148]\], exhibited no difference in BW from those of untreated mice ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}B). Mice treated with either pemafibrate or fenofibrate exhibited significantly higher liver weight ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}C), a trend toward lower eWAT ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}D) and significantly lower iWAT and BAT weights ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}E,F) than did untreated mice. While no difference in plasma glucose levels was observed between mouse groups ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}G), pemafibrate significantly decreased plasma insulin levels and fenofibrate treatment trended toward decreased plasma insulin level ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}H). Plasma TG levels in both agonist-administered mice were significantly lower than those of untreated mice, with pemafibrate having greater effects than fenofibrate ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}I). Pemafibrate treatment trended toward decreased plasma TC levels compared with untreated mice but the difference was not significant ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}J). Fenofibrate significantly increased plasma TC levels compared with untreated and pemafibrate-treated mice ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}J). Pemafibrate significantly decreased plasma FFA levels compared with untreated mice ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}K). Both agonists markedly increased plasma FGF21 to the same levels ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}L). There was no difference in plasma AST levels among mouse groups ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}M). Both agonists significantly increased plasma ALT levels compared with untreated mice but there were no differences between the two agonists ([Figure 7](#ijms-19-02148-f007){ref-type="fig"}N). Taken together, these results indicate that the toxicities of both agonists used in this study were comparable. Hepatic morphological analysis with HE staining revealed no apparent differences between mouse groups ([Figure 8](#ijms-19-02148-f008){ref-type="fig"}A). There were no differences in liver TG contents between mouse groups ([Figure 8](#ijms-19-02148-f008){ref-type="fig"}B). However, the liver TC contents in agonist-treated mice were significantly higher than those of untreated mice ([Figure 8](#ijms-19-02148-f008){ref-type="fig"}C). No morphological differences in eWAT, or BAT were observed between any of the groups of mice ([Figure 8](#ijms-19-02148-f008){ref-type="fig"}D,F). In iWAT, both PPARα agonists decreased the size of adipocytes ([Figure 8](#ijms-19-02148-f008){ref-type="fig"}E). Both agonists significantly increased the expression of *Ppara* and its target genes *Ppargc1a*, *CrebH*, *Fgf21*, *Acox1* and *Cpt1a* in the liver ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}A). Pemafibrate treatment resulted in greater increases in the expression of *Fgf21*, *Acox1* and *Cpt1a* than did fenofibrate; in contrast, fenofibrate treatment caused greater increases in *Ppara* and *Ppargc1a* expression ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}A). In eWAT, *Ppara* expression was lower in mice treated with either agonist. Treatment with pemafibrate but not fenofibrate decreased *Fgf21* expression. Fenofibrate treatment increased *Ucp1* expression ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}B). Pemafibrate-treated mice trended toward increased *Atgl* expression in eWAT compared with untreated and fenofibrate-treated mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}B). In iWAT, pemafibrate treatment did not alter the expression of any PPAR family molecules (*Ppara*, *Pparg* and *Ppard*), PPAR target genes (*Fgf21*, *Cpt1a* and *Cpt1b*), or the beige genes *Prdm16* and *Cidea* ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}C). Surprisingly, the expression of *Ucp1*, a thermogenic marker, was markedly increased in pemafibrate-treated mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}C). In BAT, the expression of *Ppara* and *Fgf21* was decreased and that of *Ucp1* and *Cpt1b* was unchanged in BAT of mice treated with either agonist ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}D). The expression of *Elovl3*, a thermogenic marker gene, was robustly increased in pemafibrate-treated mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}D).

2.6. Pemafibrate-Induced Gene Expression Partially Depends on FGF21 {#sec2dot6-ijms-19-02148}
-------------------------------------------------------------------

To determine the role of FGF21 in pemafibrate-induced changes in gene expression, FGF21 knockout (KO) mice were fed MF diet containing 0.001% pemafibrate for 1 week. Pemafibrate increased *Atgl* expression in the eWAT of both WT and FGF21 KO mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}B), suggesting that the upregulation of these genes is not dependent on FGF21. Surprisingly, pemafibrate-induced *Ppara* expression in iWAT was not observed in FGF21 KO mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}C), indicating that FGF21 regulates *Ppara* expression in iWAT. Moreover, the pemafibrate-induced *Ucp1* expression seen in the iWAT of WT mice was not observed in FGF21 KO mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}C). Similarly, the pemafibrate-induced *Elovl3* expression seen in the BAT of WT mice was not observed in FGF21 KO mice ([Figure 9](#ijms-19-02148-f009){ref-type="fig"}D). Taken together, these findings suggested that pemafibrate-induced hepatic FGF21 production enhances FGF21 signaling in WATs and BAT, leading to browning and thermogenesis in these tissues.

3. Discussion {#sec3-ijms-19-02148}
=============

Our results show that pemafibrate significantly suppressed HFD-induced body weight gain, decreased plasma glucose, insulin and triglyceride (TG) levels and increased plasma FGF21 expression in DIO mice. Pemafibrate activated PPARα transcriptional activity in the liver, thereby increasing both hepatic expression and plasma levels of FGF21. In addition, pemafibrate increased the expression of genes involved in thermogenesis and fatty acid oxidation in iWAT and BAT, suggesting that pemafibrate activates thermogenesis in iWAT and BAT by increasing plasma levels of FGF21. Additionally, pemafibrate induced the expression of *Atgl* and *Hsl* in eWAT, leading to the activation of lipolysis. Taken together, these findings indicate that pemafibrate suppresses DIO in mice.

PPARα agonists are reported to suppress obesity and obesity-induced abnormalities in glucose metabolism \[[@B2-ijms-19-02148],[@B9-ijms-19-02148],[@B30-ijms-19-02148],[@B31-ijms-19-02148],[@B32-ijms-19-02148]\]. Moreover, PPARα agonist treatment increases circulating levels of FGF21 in rodents as well as humans \[[@B33-ijms-19-02148]\], suggesting that treatment with a PPARα agonist increases FGF21 signaling in peripheral tissues and improves energy homeostasis. Surely, FGF21 treatment reduces body weight and improves glucose metabolism in mouse models of obesity and diabetes \[[@B22-ijms-19-02148],[@B23-ijms-19-02148],[@B34-ijms-19-02148],[@B35-ijms-19-02148]\]. Compared with classical PPARα agonists, pemafibrate is a novel selective PPARα modulator that increases PPARα transcriptional activity with high selectivity and potency \[[@B10-ijms-19-02148],[@B11-ijms-19-02148],[@B28-ijms-19-02148]\].

We observed that both PPARα agonists strongly suppress BW as well as WAT weight gain in DIO mice. A previous report only indicates that pemafibrate attenuates postprandial hypertriglyceridemia by suppressing the postprandial increase in chylomicrons and the accumulation of chylomicron remnants more effectively than fenofibrate in DIO mice \[[@B36-ijms-19-02148]\]. Therefore, the mechanism of suppression of BW by pemafibrate remains unknown.

Pemafibrate clearly suppressed HFD-induced obesity with no difference in food intake between untreated and pemafibrate-treated mice. This result indicates that pemafibrate increases energy expenditure. PPARα is predominantly expressed in the liver, where it plays a crucial role in many physiological functions, such as the maintenance of whole-body fatty acids and TG metabolism. Pemafibrate significantly increased the expression of *Cpt1a* and *Acox1* genes involved in fatty acid oxidation in the liver, suggesting that this increased expression contributes to the activation of hepatic fatty acid oxidation and the subsequent decrease in plasma TG levels. PPARα is also expressed in WAT and several reports show that the direct activation of PPARα in WAT can regulate WAT functions \[[@B31-ijms-19-02148],[@B32-ijms-19-02148],[@B37-ijms-19-02148],[@B38-ijms-19-02148],[@B39-ijms-19-02148]\]. Moreover, PPARα activation in WAT reportedly increases β-oxidation related gene expression, fatty acid oxidation and oxygen consumption rate \[[@B31-ijms-19-02148],[@B39-ijms-19-02148]\]. PPARα agonist treatment reportedly increases the hepatic expression and plasma levels of FGF21, resulting in the activation of FGF21 signaling in WATs \[[@B24-ijms-19-02148]\]. The PPARα agonist--FGF21--WAT interaction may contribute to the anti-obesity effect of PPARα agonists. Clearly, chronic administration of FGF21 in mice increases energy expenditure and causes weight loss \[[@B22-ijms-19-02148],[@B23-ijms-19-02148]\]. Consistent with this possibility, pemafibrate treatment markedly increased hepatic *Fgf21* expression and plasma FGF21 levels, partially explaining the weight loss effect by pemafibrate.

PPARα directly activates *Atgl* and *Hsl* expression in WAT, inducing lipolysis \[[@B40-ijms-19-02148]\]. Plasma FGF21 can cross the blood--brain barrier \[[@B41-ijms-19-02148]\] and activate the central nervous system \[[@B42-ijms-19-02148]\]. Accordingly, FGF21 activates browning in WAT, accompanied by inducing the expression of *Ucp1* and lipolysis genes such as *Atgl* and *Hsl* via the sympathetic nervous system \[[@B43-ijms-19-02148]\]. Lipolysis in WATs is activated by β3 adrenergic receptor signaling, which increases the expression of *Hsl* and *Atgl*. Activation of this pathway decreases the weight and the lipid droplet size of WATs. Although both agonists induced similar plasma levels of FGF21 HFD-fed mice, only pemafibrate activated the expression of these genes in eWATs. FGF21 deficiency did not suppress pemafibrate-induced expression of these genes, indicating that FGF21 is not involved in their expression in eWATs. Therefore, pemafibrate specifically induces *Atgl* and *Hsl* expression in eWAT.

UCP1 generates heat during thermogenesis by uncoupling oxidative phosphorylation \[[@B44-ijms-19-02148]\]. Thermogenesis inversely correlates with body mass index and adiposity \[[@B45-ijms-19-02148],[@B46-ijms-19-02148],[@B47-ijms-19-02148]\], suggesting that the activation of BAT during thermogenesis protects against obesity and obesity-related metabolic disorders. Pemafibrate treatment induced *Ucp1* expression in iWAT but not in BAT. Recent studies have addressed the conversion of white adipocytes to BAT-like white adipocytes expressing *Ucp1* mRNA. UCP1-expressing brown-like adipocytes (called as beige/bright cells) arise in iWAT in response to cold exposure and β-adrenergic receptor agonists \[[@B48-ijms-19-02148],[@B49-ijms-19-02148]\]. These cells have thermogenic capacity and can protect mice against DIO \[[@B50-ijms-19-02148],[@B51-ijms-19-02148]\]. *UCP1* promoter contains a PPRE, the consensus sequence for PPAR family molecules \[[@B52-ijms-19-02148]\], suggesting that pemafibrate activates *Ucp1* expression by activating PPARα transcriptional activity. A recent study reports that FGF21 induces the conversion of WAT adipocytes to BAT-like adipocytes by inducing the expression of thermogenic genes, including *Ucp1*, *Cidea* and *Cpt1b* \[[@B24-ijms-19-02148]\]. Consistent with this observation, we observed that pemafibrate induces the expression of the thermogenic markers *Ucp1*, *Cidea* and *Cpt1b* expression in iWAT, further supporting the premise that pemafibrate increases thermogenesis and converts cells into BAT-like adipocytes. This cellular change partially explains how pemafibrate suppresses HFD-induced adiposity. Because these genes are PPARα targets \[[@B53-ijms-19-02148]\], pemafibrate may directly affect PPARα transcriptional activity in iWAT, leading to increased gene expression. FGF21 acts directly on BAT and iWAT to increase glucose uptake and substrate mobilization \[[@B54-ijms-19-02148]\]. We observed that the pemafibrate-induced *Ucp1* expression seen in the iWAT of WT mice fed with MF diet did not occur in FGF21 KO mice. Therefore, pemafibrate-PPARα-induced FGF21 induces *Ucp1* expression in iWAT.

*Elovl3* is highly increased in BAT in response to cold exposure \[[@B55-ijms-19-02148]\] and Elovl3 KO mice exhibit defects in lipid recruitment to BAT upon cold exposure \[[@B56-ijms-19-02148]\]. *Elovl3* deficiency leads to a shortage in the fuel supply for fatty acid oxidation. Therefore, Elovl3 is used as a marker for the activation of mitochondria function \[[@B57-ijms-19-02148]\]. BAT activation is accompanied by increased expression of genes related to energy expenditure and fatty acid metabolism, including UCP1 and Elovl3. A previous report suggests that the *Elovl3* promoter contains a putative PPRE \[[@B58-ijms-19-02148]\]. Our data reveal that pemafibrate markedly increased *Elovl3* expression in BAT but did not change *Ppara* or *Fgf21* expression, indicating that pemafibrate does not mediate PPARα activation in BAT. In addition, FGF21-deficient mice fed with MF diet were completely suppressed in *Elovl3* expression. Taken together, our data indicate that the pemafibrate-induced expression of *Elovl3* in BAT is mainly regulated by plasma FGF21.

In conclusion, we observed that compared to the dose of fenofibrate, the relatively low dose of pemafibrate ameliorate obesity-induced abnormalities in DIO mice. The thermogenic functions in the iWAT and BAT of mice treated with pemafibrate were increased via increased hepatic FGF21 production and the direct effects of pemafibrate on PPARα in peripheral tissues, leading to the amelioration of obesity-induced dysfunction. Pemafibrate clearly increased *Ucp1* expression in iWAT, activating browning and thermogenesis. Fenofibrate induced not only *Ppara* but also *Ppard*, whereas pemafibrate induced only *Ppara* in iWAT. Consistent with previous our report that pemafibrate binds to the entire cavity region of ligand-binding pocket of PPARα \[[@B10-ijms-19-02148]\], pemafibrate has the selectivity and power for PPARα activity. These findings indicate that pemafibrate is more selective and powerful than fenofibrate for the improvement of obesity-induced abnormalities in DIO mice.

4. Materials and Methods {#sec4-ijms-19-02148}
========================

4.1. Reagent {#sec4dot1-ijms-19-02148}
------------

Pemafibrate was kindly provided by Kowa Co. Ltd. (Nagoya, Japan).

4.2. Animals {#sec4dot2-ijms-19-02148}
------------

Male C57BL/6J (wild-type, WT) mice were obtained from CLEA Japan. FGF21 knockout (KO) mice were kindly provided by Nobuyuki Itoh and Morichika Konishi at Kyoto University. Six-week-old male WT mice were fed MF diet plus 0.001% pemafibrate or 0.2% fenofibrate for 1 week. Eight-week-old male WT mice were fed HFD; D12492, Research Diet) plus 0.00033% pemafibrate or 0.2% fenofibrate for 12 weeks. Six-week-old WT mice were fed HFD for 8 weeks and then fed HFD plus 0.00033% pemafibrate or 0.2% fenofibrate for 4 weeks. For the OGTT, mice were fasted for 6 h and then orally administered glucose (2 g/kg body weight) after 10 weeks on the HFD. For the ITT, mice were fasted for 4 h and then injected intraperitoneally with regular insulin (Eli Lily) (0.5 U/kg body weight) after 11 weeks on the HFD. All animal husbandry procedures and experiments (17-225) were in compliance with the University of Tsukuba's Regulations for Animal Experiments and were approved by the Animal Experiment Committee at the University of Tsukuba on 1 June 2017.

4.3. Metabolic Measurements {#sec4dot3-ijms-19-02148}
---------------------------

Plasma levels of glucose, insulin, TG, FFA, TC, FGF21, ALT and AST and liver TG and TC levels were measured as described previously \[[@B59-ijms-19-02148]\].

4.4. Histological Analysis {#sec4dot4-ijms-19-02148}
--------------------------

Livers, WATs (iWAT and eWAT) and BATs were fixed; embedded in paraffin; sectioned; and stained with HE, as described previously \[[@B16-ijms-19-02148]\].

4.5. Analysis of Gene Expression {#sec4dot5-ijms-19-02148}
--------------------------------

Total RNA from cells and tissues was prepared using Sepasol (Nacalai, Kyoto, Japan). Before real-time polymerase chain reaction (PCR) analyses, total RNA was reverse transcribed into cDNA using reverse transcriptase according to the manufacturer's instructions (Takara Bio, Kusatsu, Japan). Real-time PCR was performed using the ABI Prism 7300 system (ABI, Foster City, CA, USA) and the Thermal Cycler Dice Real Time System II (Takara Bio, Kusatsu, Japan) with TB Green Premix Ex Taq II (Takara Bio). Primer sequences are described in [Table 1](#ijms-19-02148-t001){ref-type="table"}.

4.6. Statistical Analyses {#sec4dot6-ijms-19-02148}
-------------------------

Treatment groups were compared using the Tukey--Kramer post-hoc test and differences were considered significant for *p* \< 0.05. All data are expressed as mean ± standard error of the mean.
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Acox1

acyl-CoA oxidase 1

Adrb3

adrenergic receptor, beta 3

ALT

alanine aminotransferase

AST

aspartate aminotransferase

Atgl

adipose triglyceride lipase

BAT

brown adipose tissue

Cidea

cell death-inducing DFFA-like effector a

Cpt1a

carnitine palmitoyl transferase 1a

Cpt1b

carnitine palmitoyl transferase 1b

CREBH

cAMP-responsive element-binding protein H

DIO

diet-induced obesity

Elovl3

ELOVL fatty acid elongase 3

eWAT

epididymal white adipose tissue

FFA

Free fatty acid

FGF21

fibroblast growth factor 21

FGFR1

FGF receptor 1

OGTT

oral glucose tolerance test

HDL

high-density lipoprotein

HE

hematoxylin and eosin

HFD

high-fat diet

Hsl

hormone sensitive lipase

ITT

insulin tolerance test

iWAT

inguinal adipose tissue

KO

knockout

MF

modest fat

Ppargc1a

peroxisome proliferative-activated receptor, gamma, coactivator 1 alpha

PPARα

peroxisome proliferator-activated receptor α

PPRE

PPAR response element

Prdm16

PR domain containing 16

TC

total cholesterol

TG

triglyceride

UCP1

uncoupling protein 1

WT

wild type

![Pemafibrate reduces plasma lipid levels in WT mice fed with high-fat diet (HFD) for 12 weeks. Six-week-old male WT mice were fed HFD plus pemafibrate (0.00033%) or fenofibrate (0.2%) for 12 weeks (**A**); (**B**) Representative pictures of mice; (**C**) body growth curve; †† *p* \< 0.01; untreated mice vs. pemafibrate- and fenofibrate-treated mice; (**D**) liver weight; (**E**) eWAT weight; (**F**) iWAT weight; (**G**) BAT weight; and concentrations of (**H**) plasma glucose; (**I**) insulin; (**J**) TG; (**K**) TC; (**L**) FFA; (**M**) FGF21; (**N**) AST and (**O**) ALT. All values are the means ± standard error of the mean (SEM). *n* = 9 per group; \* *p* \< 0.05; \*\* *p* \< 0.01.](ijms-19-02148-g001){#ijms-19-02148-f001}

![Histological analysis shows that pemafibrate reduces lipid content and cell size in liver and WATs in high-fat diet (HFD)-fed WT mice. Six-week-old male WT mice were fed HFD plus pemafibrate (0.00033%) or fenofibrate (0.2%) for 12 weeks. HE staining analysis in liver (**A**), eWAT (**D**), iWAT (**E**) and BAT (**F**). Liver TG (**B**) and TC (**C**) concentrations; All values are the means ± SEM. *n* = 9 per group; Scale bar: 100 μm.](ijms-19-02148-g002){#ijms-19-02148-f002}

![Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) in high-fat diet (HFD)-fed WT mice treated with pemafibrate. Six-week-old male WT mice were fed HFD plus pemafibrate (0.00033%) or fenofibrate (0.2%) for 10 weeks. (**A**,**B**) Results of OGTT of these mice. Plasma glucose (**A**) and insulin levels (**B**) during OGTT. (**C**) Results of ITT of mice treated with pemafibrate for 11 weeks. Plasma glucose levels during ITT; All values are the means ± SEM. *n* = 9 per group; †† *p* \< 0.01; untreated mice vs. pemafibrate- and fenofibrate-treated mice.](ijms-19-02148-g003){#ijms-19-02148-f003}

![Gene expression in WT mice fed with high-fat diet (HFD) plus pemafibrate for 12 weeks. Six-week-old male WT mice were fed HFD and treated with or without pemafibrate (0.00033%) or fenofibrate (0.2%) for 12 weeks. Gene expression profiles of the liver (**A**), eWAT (**B**), iWAT (**C**) and BAT (**D**); All values are the means ± SEM. *n* = 9 per group; \* *p* \< 0.05; \*\* *p* \< 0.01.](ijms-19-02148-g004){#ijms-19-02148-f004}

![Pemafibrate reduces plasma lipid levels in high-fat diet (HFD)-fed WT mice treated with pemafibrate. Six-week-old male WT mice were fed HFD for 8 weeks and treated with pemafibrate (0.00033%) or fenofibrate (0.2%) for 4 weeks (**A**). (**B**) Representative pictures of mice; (**C**) body growth curve, ↓; start of agonist treatment, ‡‡ *p* \< 0.01; untreated mice vs. fenofibrate-treated mice, †† *p* \< 0.01; untreated mice vs. pemafibrate- and fenofibrate-treated mice; (**D**) liver weight; (**E**) eWAT weight; (**F**) iWAT weight; (**G**) BAT weight; and concentrations of (**H**) plasma glucose, (**I**) insulin, (**J**) TG, (**K**) TC, (**L**) FFA, (**M**) FGF21, (**N**) AST and (**O**) ALT. All values are the means ± SEM. *n* = 9 per group; \* *p* \< 0.05; \*\* *p* \< 0.01.](ijms-19-02148-g005){#ijms-19-02148-f005}

![Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) of high-fat diet (HFD)-induced obese mice treated with pemafibrate. Six-week-old male WT mice were fed HFD for 8 weeks and then treated with pemafibrate (0.00033%) or fenofibrate (0.2%). (**A**,**B**) Results of OGTT of mice treated with pemafibrate or fenofibrate for 2 weeks. Plasma glucose (**A**) and insulin levels (**B**) during OGTT. (**C**) Results of ITT of mice treated with pemafibrate or fenofibrate for 3 weeks. Plasma glucose levels during ITT. All values are the means ± SEM. *n* = 9 per group; †† *p* \< 0.01 untreated mice vs. pemafibrate- and fenofibrate-treated mice.](ijms-19-02148-g006){#ijms-19-02148-f006}

![Pemafibrate reduces plasma lipid levels in WT mice fed with (modest-fat) MF diet. Eleven-week-old male WT mice were fed MF diet plus pemafibrate (0.001%) or fenofibrate (0.2%) for 1 week. Body weight (**A**); liver weight (**B**); eWAT weight (**C**); iWAT weight (**D**); BAT weight (**E**); muscle weight (**F**); and concentrations of plasma glucose (**G**), insulin (**H**), TG (**I**), TC (**J**), FFA (**K**), FGF21 (**L**), AST (**M**) and ALT (**N**). All values are the means ± SEM. *n* = 8 per group; \* *p* \< 0.05; \*\* *p* \< 0.01.](ijms-19-02148-g007){#ijms-19-02148-f007}

![Histological analysis shows that pemafibrate reduces lipid contents and cell size in the liver and WATs in MF-diet fed WT mice. Eleven-week-old male WT mice were fed MF diet plus pemafibrate (0.001%) or fenofibrate (0.1%) for 1 week. HE staining analysis of liver (**A**), eWAT (**D**), iWAT (**E**), BAT (**F**) and concentrations of liver TG (**B**) and TC (**C**). All values are the means ± SEM. *n* = 8 per group; \*\* *p* \< 0.01; *n* = 9--13 per group. Scale bar: 100 μm.](ijms-19-02148-g008){#ijms-19-02148-f008}

![Gene expression in WT mice fed with MF diet plus pemafibrate for 1 week. Eleven-week-old male WT and FGF21 KO mice were fed MF diet plus pemafibrate (0.001%) or fenofibrate (0.1%) for 1 week. Gene expression profiles of the liver (**A**), eWAT (**B**), iWAT (**C**) and BAT (**D**). All values are the means ± SEM. *n* = 8 per group; \* *p* \< 0.05; \*\* *p* \< 0.01.](ijms-19-02148-g009){#ijms-19-02148-f009}
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###### 

List of QPCR primer sequences.

  *Gene*          Forward Primer               Reverse Primer
  --------------- ---------------------------- --------------------------
  *Acox1*         CGATCCAGACTTCCAACATGAG       CCATGGTGGCACTCTTCTTAACA
  *Adrb3*         ACAGGAATGCCACTCCAATC         TTAGCCACAACGAACACTCG
  *Atgl*          GGATGGCGGCATTTCA             CAAAGGGTTGGGTTGG
  *Cebpa*         GCGCAAGAGCCGAGATAAAG         CGGTCATTGTCACTGGTCAACT
  *Cidea*         CATCCCCCAAGCCTAG             CTCTGTAGCTGTGCCC
  *Cpt1a*         CCTGGGCATGATTGCAAAG          GGACGCCACTCACGATGTT
  *Cpt1b*         GGCTGCCGTGGGACATT            TGCCTTGGCTACTTGGTACGA
  *CrebH*         CCTGTTTGATCGGCAGGAC          CGGGGGACGATAATGGAGA
  *Cyclophilin*   TGGCTCACAGTTCTTCATAACCA      ATGACATCCTTCAGTGGCTTGTC
  *Elovl3*        CGTAGTCAGATTCTGG             CCAGAAGAAGTGTTCC
  *Fgf21*         AGATCAGGGAGGATGGAACA         TCAAAGTGAGGCGATCCATA
  *Hsl*           GAGCGCTGGAGGAGTGTTTT         TGATGCAGAGATTCCCACCTG
  *Ppara*         ACGCGAGTTCCTTAAGAACCTG       GTGTCATCTGGATGGTTGCTCT
  *Ppard*         TTCCACTATGGAGTTCATGCTTG      TCCGGCAGTTAAGATCACACCT
  *Pparg*         TCAACATGGAATGTCGGGTG         ATACTCGAGCTTCATGCGGATT
  *Ppargc1a*      TTCAAGATCCTGTTACTACT         ACCTTGAACGTGATCTCACA
  *Prdm16*        GGCGAGGAAGCTAGCC             GGTCTCCTCCTCGGCA
  *Ucp1*          AGGATGGTGAACCCGACAAC         TTGGATCTGAAGGCGGACTT
  *Ucp2*          GACCTCATCAAAGATACTCTCCTGAA   ATCTCGTCTTGACCACATCAACAG
